Interaction risk with statin switch;Interaksjonsrisiko ved statinbytte

Tidsskrift for den Norske Laegeforening

Volumn 127, Issue 4, 2007, Pages 428-431

  Molden, Espen ^a   Westergren, Tone ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847045597     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Walley T, Folino-Gallo P, Stephens P et al. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60: 543-51.
2. Statens legemiddelverk. Statiner - nye vilkår for refusjon (13.04.2005). www.legemiddelverket.no/ (1.8.2006).
3. www.legemiddelforbruk.no (1.8.2006).
4. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
5. Stern R, Abel R, Gibson GL et al. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 1997; 37: 1062-4.
6. Lin JC, Ito MK, Stolley SN et al. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39: 86-90.
7. Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 2003; 89: 949-50.
8. Sconce EA, Khan TI, Daly AK et al. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 2006; 4: 1422-4.
9. Siedlik PH, Olson SC, Yang BB et al. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999; 39: 501-4.
10. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-82.
11. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65.
12. Mazzu AL, Lasseter KC, Shamblen EC et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000; 68: 391-400.
13. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140-6.
14. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-41.
15. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 2002; 42: 444-9.
16. Hsyu PH, Schultz-Smith MD, Lillibridge JH et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445-50.
17. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. Aids 2002; 16: 569-77.
18. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-15.
19. Sakaeda T, Fujino H, Komoto C et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006; 23: 506-12.
20. Hillman MA, Wilke RA, Caldwell MD et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 14: 539-47.
21. Pautas E, Gouin-Thibault I, Debray M et al. Haemorrhagic complications of vitamin K antagonists in the elderly: risk factors and management. Drugs Aging 2006; 23: 13-25.
22. Reikvam A, Madsen S, Landmark K. Antitrombotisk profylakse etter hjerteinfarkt - acetylsalisylsyre, warfarin eller begge? Tidsskr Nor Lægeforen 2003; 123: 1838-40.
23. Grau E, Perella M, Pastor E. Simvastatin-oral anticoagulant interaction. Lancet 1996; 347: 405-6.
24. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107.
25. Bae J, Jarcho JA, Denton MD et al. Statin specific toxicity in organ transplant recipients: case report and review of the literature. J Nephrol 2002; 15: 317-9.
26. Kanathur N, Mathai MG, Byrd RP jr. et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-41.
27. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-8.
28. Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002; 36: 1546-9.
29. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-7.
30. Antons KA, Williams CD, Baker SK et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9.
31. Statens legemiddelverk. Preparatomtale (SPC) Zocor. www.legemiddelverket. no/preparatomtaler (Sist endret: 24. februar 2006) (1.8.2006).
32. Mousa O, Brater DC, Sunblad KJ et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-74.
33. Watanabe H, Kosuge K, Nishio S et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281-92.
34. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004; 24: 285-90.
35. Åsberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367-78.